INmune Bio has submitted the final pre-Marketing Authorisation Application package for Ebstrocel™, a cell therapy for recessive dystrophic epidermolysis bullosa, to the UK MHRA. The company updated its strategy to submit the full application by early February 2027, potentially accelerating UK approval to mid-2027. In parallel, INmune Bio plans to submit a Biologics License Application to the US FDA in Q2 2027. These steps mark significant progress toward regulatory approvals in key markets, bringing the therapy closer to patients with this rare disease.
INmune Bio's progress toward UK approval for Ebstrocel™ comes as 71 of 150 Health-sector US stocks on Pluang rose today. For readers following Health-sector stocks, here is Pluang's market snapshot as of Oct 21, 2026 18:11 WIB: Bruker Corporation (BRKR) traded at USD 54.99 with a 1-day change of -1.68% and a typical hold time of 12 days; Heron Therapeutics (HRTX) was at USD 0.36, up 1.55%, with a typical hold time of 37 days and Pluang order activity split 48% Sell / 52% Buy; Amphastar Pharmaceuticals (AMPH) traded at USD 25.58, down 1.39%, with a typical hold time of 17 days.
The Human Feedback Foundation, supported by RBC, has launched the Agentic AI Design Exchange, a national program aimed at helping Canadian nonprofits design, build, and deploy AI agents responsibly. Funded through RBC's Stronger Nonprofits Program, t...
Satellos Bioscience Inc., a clinical-stage company focused on treatments for degenerative muscle diseases, announced its management will participate in two investor conferences in November: the Guggenheim Healthcare Innovation Conference on Nov 9 in ...
YYForce Inc. has purchased 20 wearable data collection systems to gather real task data from hotel room service at Novotel Singapore. This project aims to record and analyze experienced staff performing tasks like bed-making, towel folding, and clean...
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, at a compound annual growth rate of 20.2%. This growth is driven by increasing demand for chronic disease managem...
The global private credit and alternative lending market, valued at $2.31 trillion in 2026, is expected to grow at a 7.8% CAGR to reach $3.36 trillion by 2031. Recent liquidity pressures in 2025, triggered by bankruptcies and AI sector concerns, caus...
